

31st October, 2022

To,
The BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400001

Dear Sir

Sub : Outcome of the Board Meeting under Regulation 30 and 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

BSE Code : 531210

We would like to inform you that, the Board of Directors of the Company at their meeting held today i.e. 31st October, 2022 has, inter alia considered and approved Unaudited Financial Results (as per IND-AS) for the quarter and half year ended on 30th September, 2022.

Enclosed herewith the same (Unaudited Financial Results for the quarter and half year ended on 30th September, 2022) along with a Limited Review Report dated 31st October, 2022 issued by M/s. Vora & Associates, Chartered Accountants and Statutory Auditors of the Company with respect to Unaudited Financial Results for the quarter and half year ended on 30th September, 2022.

The Meeting commenced at 3:30 PM and concluded at 4.30 p.m.

This is for your information and record.

Thanking you,

Yours faithfully,

FOR COLINZ LABORATORIES LTD

DR. MANI L.S.
Director & Company Secretary
DIN: 00825886



Colinz Laboratories Limited

CIN NO- L24200MH1986PLC041128

Corp.Off.: A/101, Pratik Estate, Next to Fortis Hospital, Mulund Link Road, P. Box No. 17339 Mumbai - 400 078. INDIA

E-mail : colinzlabs@yahoo.com / colinzlabs@gmail.com

Tel:- +91-22-2566 8002 / 8003 Fax :- +91-22-2566 8006



VORA & ASSOCIATES
CHARTERED ACCOUNTANTS

101-103, REWA CHAMBERS
31, NEW MARINE LINES
MUMBAI - 400 020. INDIA

91-99305 75933
022-2200 5933 - 2200 5934
www.cavoras.com
office@cavoras.com
cavoras@gmail.com

Independent Auditor's Review Report on Unaudited Quarterly Financial Results

To
The Board of Directors,
COLINZ LABORATORIES LIMITED.

We have reviewed the accompanying statement of unaudited financial results ('the Statement') of **COLINZ LABORATORIES LIMITED** ('the Company') for the quarter and half year ended 30th September, 2022 being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).

This statement, which is the responsibility of the Company's Management and has been approved by the Board of Directors has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34') prescribed u/s 133 of the Companies Act, 2013 ('the Act'), SEBI Circular CIR/CF/FAC/62/2016 dated 05/07/2016 (hereinafter referred to as the 'the SEBI Circular') and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410 "Review of Interim Financial Statements Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with applicable accounting standards i.e. Ind AS prescribed under Section 133 of the Act read with relevant Rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

For VORA & ASSOCIATES
CHARTERED ACCOUNTANTS
(ICAI Firm Reg. No.: 111612W)


RONAK A. RAMBHIA
PARTNER

(Membership No.: 140371)

UDIN: 22140371BBLEVB9686
PLACE: MUMBAI
DATED: October 31, 2022

COLINZ LABORATORIES LIMITED.

(CIN NO: L24200MH1986PLC041128)

A-101, Pratik Ind. Estate, Next to Fortis Hospital, Mulund-Goregaon Link Road, Mumbai - 400 078.

UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED "" 30TH SEPTEMBER-2022""

""(Rupees in Lakhs)""

S. No.	PARTICULARS	UN-AUDITED					AUDITED
		QUARTER ENDED			SIX MONTH ENDED		YEAR ENDED
		30-Sep-2022	30-Jun-2022	30-Sep-2021	30-Sep-2021	30-Sep-2022	31-Mar-2022
PART-I							
1	(a) Revenue from Operation	191.65	183.81	195.07	380.11	375.46	697.42
2	(b) Other Income	4.51	4.12	2.90	7.04	8.63	17.08
3	Total Revenue from Operation (a+b)	196.16	187.93	197.97	387.15	384.09	714.50
4	Expenses						
	a) Cost Of Material Consumed	27.96	18.41	15.74	32.40	46.37	60.13
	b) Purchase of Stock in Trade	24.80	53.43	41.71	74.38	78.23	136.92
	c) Change in Inventories Of Finished Goods and Work in Progress of Stock in trade.	12.73	(14.78)	6.44	16.99	(2.05)	32.80
	d) Employee Benefit Expenses	76.95	78.74	76.64	150.47	155.69	290.30
	e) Finance Cost	1.32	1.23	1.91	3.92	2.55	7.55
	f) Depreciation & Amortisation Expenses	3.22	3.22	4.98	9.96	6.44	20.11
	g) Other Expenses	32.52	33.40	36.94	74.22	65.92	118.66
	Total Expenses	179.50	173.65	184.36	362.34	353.15	666.47
5	Profit /(Loss) Before exceptional items and tax (16.66	14.28	13.61	24.81	30.94	48.03
6	Exceptional items						
7	Profit /(Loss) before tax (5-6)	16.66	14.28	13.61	24.81	30.94	48.03
8	Tax Expenses (Provision for Taxation) Current tax						
	i) Current Tax	5.00	3.25	3.71	6.46	8.25	14.35
	ii) Tax for earlier years	-	-	-	-	-	(0.97)
	iii) MAT Credit of Earlier years	-	-	-	-	-	0.72
	iv) Deferred Tax	-	-	-	-	-	-
9	Profit /(Loss) for the period from continuing operations(7-8)	11.66	11.03	9.90	18.35	22.69	33.93
10	Profit /(Loss) from discontinued operations	-	-	-	-	-	-
11	Tax expenses of discontinued operations	-	-	-	-	-	-
12	Profit /(Loss) for the period (9+10-11)	11.66	11.03	9.90	18.35	22.69	33.93
13	Other Comprehensive Income (NET OF TAX)						
	A) i) Item that will not be reclassified to Profit or	10.05	(6.05)	5.85	10.51	4.00	5.68
	ii) Income tax relating to items that will not be reclassified to Profit or Loss	-	-	-	-	-	-
14	Total Comprehensive Income for the period (12+13) Comprising Profit /(Loss) and Other	21.71	4.98	15.75	28.86	26.69	39.61
15	Earning per equity share (for Continuing operation)						
	i) Basic	0.46	0.44	0.34	0.63	0.90	0.74
	ii) Diluted	0.46	0.44	0.34	0.63	0.90	0.74

Colinz Laboratories Limited

CIN NO- L24200MH1986PLC041128

Corp.Off.: A/101, Pratik Estate, Next to Fortis Hospital, Mulund Link Road, P. Box No. 17339 Mumbai - 400 078. INDIA

E-mail : colinzlabs@yahoo.com / colinzlabs@gmail.com

Tel:- +91-22-2566 8002 / 8003 Fax :- +91-22-2566 8006

STATEMENT OF ASSETS AND LIABILITIES				
Particulars			30-Sep-2022	31-Mar-2022
Non-Current Assets				
a) Property, Plants & Equipment			177.37	186.19
b) Capital Work-in progress			-	-
c) Intangible Assets			-	-
d) Financial Assets				
i) Investments			71.37	66.91
ii) Loans			-	-
iii) Other Financial Assets			-	-
e) Other Non Current Assets			2.99	2.13
Total Non-Current Assets			251.73	255.23
Current Assets				
a) Inventories			89.34	92.52
b) Financial Assets				
i) Trade Receivables			150.75	120.59
ii) Cash & Cash Equivalents			251.74	208.82
iii) Other Bank Balances			319.15	311.82
iv) Other Financial Assets			-	-
c) Other Current Assets			4.65	4.16
Total Current Assets			815.63	737.91
TOTAL ASSETS			1067.36	993.14
EQUITY AND LIABILITIES				
Equity				
a) Equity Share Capital			251.91	354.50
b) Other Equity			543.53	414.24
Total Equity			795.44	768.74
Liabilities				
Non-Current Liabilities				
a) Deferred Tax Liabilities (Net)			22.62	22.18
b) Other Non Current Liabilities			4.07	4.07
Total Non-Current Liabilities			26.69	26.25
Current Liabilities				
a) Financial Liabilities				
i) Borrowings			57.07	48.45
ii) Trade Payables			66.77	47.51
b) Other Current Liabilities			108.84	89.64
c) Current Provisions			12.55	12.55
Total Current Liabilities			245.23	198.15
TOTAL EQUITY AND LIABILITIES			1067.36	993.14



Colinz Laboratories Limited

CIN NO- L24200MH1986PLC041128

Corp.Off.: A/101, Pratik Estate, Next to Fortis Hospital, Mulund Link Road, P. Box No. 17339 Mumbai - 400 078. INDIA

E-mail : colinzlabs@yahoo.com / colinzlabs@gmail.com

Tel:- +91-22-2566 8002 / 8003 Fax :- +91-22-2566 8006

COLINZ LABORATORIES LTD.

CASH FLOW STATEMENT FOR THE HALF YEAR ENDED 30-09-2022

A) CASH FLOW FROM OPERATING ACTIVITIES:**Profit Before Taxation****Adjustments for:**

Depreciation/Impairment

Loss on sale of Assets

Interest Expense

Interest Income

Dividend Income

Operating Profit Before Working Capital Changes**Adjustments for changes in working capital:**

Increase / (Decrease) in Trade Payable

Increase / (Decrease) in Short Term Borrowings

Increase / (Decrease) in Current Provisions

Increase / (Decrease) in Other Current Liabilities

Increase / (Decrease) in Other Long Term Current Liabilities

(Increase) / Decrease in Trade Receivables

(Increase) / Decrease in Inventories

(Increase) / Decrease in Other Non Current Assets

(Increase) / Decrease in Other Current Assets

Cash Generated / (Used In) from Operations

Taxes Paid (Net)

Net Cash generated from / (Used In) Operating Activities**B) CASH FLOW FROM INVESTING ACTIVITIES:**

Purchase of Fixed Assets

Dividend Income

Net Cash (Used In) Investing Activities**C) CASH FLOW FROM FINANCING ACTIVITIES:**

Interest received

Interest Expense

Net Cash (Used In) / generated from Financing Activities**Net increase in Cash and Cash Equivalents (A+B+C)**

Cash and Cash Equivalents as at the beginning of the year

Cash and Cash Equivalents as at the end of the year

Cash and Cash Equivalents comprise of:

Cash in Hand

Balances with Scheduled Banks in:

- Current Accounts

Other Bank Balances

	April 01, 2022 To SEPT. 30, 2022	April 01, 2021 To March 31, 2022
Profit Before Taxation	30.94	48.03
Adjustments for:		
Depreciation/Impairment	6.44	20.12
Loss on sale of Assets	2.37	-
Interest Expense	2.56	7.55
Interest Income	(8.12)	(16.58)
Dividend Income	(0.51)	(0.50)
Operating Profit Before Working Capital Changes	33.67	58.62
Adjustments for changes in working capital:		
Increase / (Decrease) in Trade Payable	19.26	(6.90)
Increase / (Decrease) in Short Term Borrowings	8.63	(50.81)
Increase / (Decrease) in Current Provisions	-	(0.70)
Increase / (Decrease) in Other Current Liabilities	19.20	(2.05)
Increase / (Decrease) in Other Long Term Current Liabilities	-	4.07
(Increase) / Decrease in Trade Receivables	(30.16)	9.18
(Increase) / Decrease in Inventories	3.18	32.13
(Increase) / Decrease in Other Non Current Assets	(0.21)	17.50
(Increase) / Decrease in Other Current Assets	(0.48)	0.74
Cash Generated / (Used In) from Operations	53.08	61.79
Taxes Paid (Net)	(8.91)	(15.07)
Net Cash generated from / (Used In) Operating Activities	44.17	46.72
B) CASH FLOW FROM INVESTING ACTIVITIES:		
Purchase of Fixed Assets	-	(3.75)
Dividend Income	0.51	0.50
Net Cash (Used In) Investing Activities	0.51	(3.25)
C) CASH FLOW FROM FINANCING ACTIVITIES:		
Interest received	8.12	16.58
Interest Expense	(2.56)	(7.55)
Net Cash (Used In) / generated from Financing Activities	5.57	9.03
Net increase in Cash and Cash Equivalents (A+B+C)	50.25	52.49
Cash and Cash Equivalents as at the beginning of the year	520.64	468.14
Cash and Cash Equivalents as at the end of the year	570.89	520.64
Cash and Cash Equivalents comprise of:		
Cash in Hand	1.29	1.02
Balances with Scheduled Banks in:		
- Current Accounts	250.45	207.80
Other Bank Balances	319.15	311.82
	570.89	520.64

Notes:

- The above cash flow statement has been prepared under the "Indirect Method" set out in Ind AS 7, "Cash Flow" issued by the Institute of Chartered Accountants of India.
- Cash and cash equivalents represent cash & bank balances and Other Bank Balances
- Previous Year's figures have been regrouped and rearranged, wherever necessary.



For and on behalf of the Board of Directors

Dr. MANI L. S.

Director &

Company Secretary

Din No- 00825886



Place: Mumbai

Date: 31-10- 2022

For and on behalf of the Board
COLINZ LABORATORIES LTD.
CIN NO : L24200MH1986PLC041128



Dr. MANI L. S.
(Director-Legal, Corporate Affairs & Company Secretary)
(DIN NO : 00825886)



Colinz Laboratories Limited

CIN NO- L24200MH1986PLC041128

Corp.Off.: A/101, Pratik Estate, Next to Fortis Hospital, Mulund Link Road, P. Box No. 17339 Mumbai - 400 078. INDIA

E-mail : colinzlabs@yahoo.com / colinzlabs@gmail.com

Tel:- +91-22-2566 8002 / 8003 Fax :- +91-22-2566 8006